International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationGamma Knife Stereotactic Radiosurgery as Salvage Therapy After Failure of Whole-Brain Radiotherapy in Patients With Small-Cell Lung Cancer
Introduction
Whole-brain irradiation (WBI) is the standard therapy for treatment of the brain in small-cell lung cancer (SCLC), either in the prophylactic setting or with known brain metastases. The rationale for WBI is primarily due to the high incidence of brain metastases in SCLC and the increased likelihood of a diffuse failure pattern of brain metastases 1, 2, 3. Evidence suggests a modest survival benefit in the setting of both limited stage and extensive stage disease with the addition of prophylactic cranial irradiation (PCI) after complete or substantive partial response to treatment of the primary site 4, 5.
Despite the relative radio-responsive nature of SCLC, disease failure in the brain after previous WBI is not uncommon (4). Historically, salvage options in this setting are limited. Repeated WBI has been reported to be minimally effective in a limited number of patients with recurrent brain metastases of all histological results, and median survival time after reirradiation is short (6). Moreover, there is scant evidence regarding reirradiation of the whole brain for SCLC and few neurocognitive toxicity data for whole-brain reirradiation in general.
GammaKnife stereotactic radiosurgery (GKSRS) has been used successfully in the salvage setting for brain metastases in patients for whom WBI has failed (7). However, given the propensity of SCLC for multiple metastases, the benefit of focal reirradiation and the factors predictive of successful outcome are unknown. The potential to spare patients from high cumulative integral radiation doses of whole-brain reirradiation makes radiosurgical salvage a potentially attractive option to avoid the increased risk of neurocognitive decline. The possibility remains, however, for multiple brain failures outside the SRS-treated lesions, and the timing and pattern of such out of field failure are poorly defined.
At our institution, we have practiced a strategy of radiosurgical salvage of brain metastases in patients with SCLC for whom WBI has previously failed. Those with four or fewer brain metastases are offered radiosurgery for salvage; however, occasionally, patients with greater numbers of metastases have been treated. We report our single-institution series documenting the failure patterns of such an approach, as well as an analysis of the disease-related factors that may affect survival, to help determine which patients may warrant salvage radiosurgery with delay or avoidance of repeat WBI.
Section snippets
Data acquisition
This study was approved by the Wake Forest University Institutional Review Board. The Wake Forest University Medical Center GammaKnife Program Tumor Registry was searched for all patients who received GKSRS and had a diagnosis of SCLC. Two patients who did not previously receive WBI were excluded. Between November 1999 and June 2009, 51 GKSRS procedures were performed at Wake Forest University Baptist Medical Center in Winston-Salem, NC, on patients with SCLC with recurrent brain metastases for
Survival
Median survival time of the entire cohort was 5.9 months. One- and 2-year overall survival rates were 24% and 15%, respectively. Kaplan-Meier plot for overall survival is shown in Figure 1. Multivariate analysis assessing factors that predicted for survival is depicted in Table 2. Multivariate analysis revealed that the status of ECD (stable or progressive vs. absent) at time of salvage GKSRS predicted for overall survival (stable, hazard ratio [HR] = 2.89; progressive, HR = 6.98, p = 0.00002).
Discussion
The role of radiosurgery in patients with SCLC for whom prophylactic or therapeutic WBI has failed is controversial. Thus far, a single additional series has been published evaluating the efficacy of GKSRS in SCLC after WBI failure. In that series, the authors reported a median overall survival time of 18 months, with an overall local control rate of 81% (3). In our series, freedom from local failure was 57% at 1 year, which is substantially worse than that generally seen for brain metastases
Conclusions
GKSRS is a modestly effective salvage treatment option for patients with SCLC for whom previous prophylactic or therapeutic WBI has failed. Patients with absent or stable extracranial oligometastatic disease have improved survival times. Local control may be inferior to that seen with other cancer histological results.
References (19)
- et al.
Analysis of outcome in patients reirradiated for brain metastases
Int J Radiat Oncol Biol Phys
(1996) - et al.
Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases
Int J Radiat Oncol Biol Phys
(2000) - et al.
Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90–05
Int J Radiat Oncol Biol Phys
(2000) - et al.
The role of prophylactic brain irradiation in limited stage small cell lung cancer: clinical, neuropsychologic, and CT sequelae
Int J Radiat Oncol Biol Phys
(1988) - et al.
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial
Lancet Oncol
(2009) - et al.
Cognitive sequelae of brain radiation in adults
Semin Oncol
(2004) - et al.
Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study
Radiother Oncol
(1998) - et al.
Stereotactic radiosurgery for patients with brain metastases from small cell lung cancer
Int J Radiat Oncol Biol Phys
(2011) - et al.
Distribution of brain metastases
Arch Neurol
(1988)
Cited by (0)
Conflict of interest: none.